TY - JOUR
T1 - MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
AU - Jiang, Yao
AU - Zhang, Yanqiong
AU - Leung, Janet Y.
AU - Fan, Cheng
AU - Popov, Konstantin I.
AU - Su, Siyuan
AU - Qian, Jiayi
AU - Wang, Xiaodong
AU - Holtzhausen, Alisha
AU - Ubil, Eric
AU - Xiang, Yang
AU - Davis, Ian
AU - Dokholyan, Nikolay V.
AU - Wu, Gang
AU - Perou, Charles M.
AU - Kim, William Y.
AU - Earp, H. Shelton
AU - Liu, Pengda
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Akt plays indispensable roles in cell proliferation, survival and metabolism. Mechanisms underlying posttranslational modification-mediated Akt activation have been extensively studied yet the Akt interactome is less understood. Here, we report that SAV1, a Hippo signaling component, inhibits Akt, a function independent of its role in Hippo signaling. Binding to a proline-tyrosine motif in the Akt-PH domain, SAV1 suppresses Akt activation by blocking Akt’s movement to plasma membrane. We further identify cancer-associated SAV1 mutations with impaired ability to bind Akt, leading to Akt hyperactivation. We also determine that MERTK phosphorylates Akt1-Y26, releasing SAV1 binding and allowing Akt responsiveness to canonical PI-3K pathway activation. This work provides a mechanism underlying MERTK-mediated Akt activation and survival signaling in kidney cancer. Akt activation drives oncogenesis and therapeutic resistance; this mechanism of Akt regulation by MERTK/SAV1 provides yet another complexity in an extensively studied pathway, and may yield prognostic information and therapeutic targets.
AB - Akt plays indispensable roles in cell proliferation, survival and metabolism. Mechanisms underlying posttranslational modification-mediated Akt activation have been extensively studied yet the Akt interactome is less understood. Here, we report that SAV1, a Hippo signaling component, inhibits Akt, a function independent of its role in Hippo signaling. Binding to a proline-tyrosine motif in the Akt-PH domain, SAV1 suppresses Akt activation by blocking Akt’s movement to plasma membrane. We further identify cancer-associated SAV1 mutations with impaired ability to bind Akt, leading to Akt hyperactivation. We also determine that MERTK phosphorylates Akt1-Y26, releasing SAV1 binding and allowing Akt responsiveness to canonical PI-3K pathway activation. This work provides a mechanism underlying MERTK-mediated Akt activation and survival signaling in kidney cancer. Akt activation drives oncogenesis and therapeutic resistance; this mechanism of Akt regulation by MERTK/SAV1 provides yet another complexity in an extensively studied pathway, and may yield prognostic information and therapeutic targets.
UR - http://www.scopus.com/inward/record.url?scp=85063951366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063951366&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-09233-7
DO - 10.1038/s41467-019-09233-7
M3 - Article
C2 - 30944303
AN - SCOPUS:85063951366
SN - 2041-1723
VL - 10
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1515
ER -